Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 9/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.41 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | ALB | P02768 | 1/20 | 0.38 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.36 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 2/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7048435 | 0.90 | FTO (0.43) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL592690 | 0.85 | FTO (0.49) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL3201232 | 0.78 | ALB (0.49) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL30366389 | 0.78 | ALB (0.49) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL7061813 | 0.77 | FTO (0.40) | FTOMEN1MAPTHPGDCYP2C19 | |
| Fluorescein SCHEMBL29996358 | 0.76 | FTO (0.52) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL15347554 | 0.74 | FTO (0.43) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL22295453 | 0.74 | FTO (0.55) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL164316 | 0.73 | FTO (0.56) | FTOMEN1MAPTHPGDCYP2C19 | |
| SCHEMBL30064563 | 0.73 | FTO (0.56) | FTOMEN1MAPTHPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1773936-A4 | UNAGGLOMERATED CORE/SHELL NANOCOMPOSITE PARTICLES | PENN STATE RES FOUND (US) | 2008-10-08 | — | — | EP | claimed |
| EP-1773936-A2 | UNAGGLOMERATED CORE/SHELL NANOCOMPOSITE PARTICLES | THE PENN STATE RESEARCH FOUNDATION (US) | 2007-04-18 | — | — | EP | claimed |
| US-20050281884-A1 | Unagglomerated core/shell nanocomposite particles | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-12-22 | — | — | US | claimed |
| WO-2005118702-A2 | UNAGGLOMERATED CORE/SHELL NANOCOMPOSITE PARTICLES | THE PENN STATE RESEARCH FOUNDATION (US) | 2005-12-15 | — | — | WO | claimed |
| US-20220305121-A1 | N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2022-09-29 | — | — | US | disclosed |
| US-11150358-B2 | Radiation dosimetry sol or gel and radiation dosimeter comprising same as material for radiation dosimetry | RIKEN (JP) | 2021-10-19 | — | — | US | disclosed |
| WO-2021034729-A1 | N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-02-25 | — | — | WO | disclosed |
| US-20200333474-A1 | RADIATION DOSIMETRY SOL OR GEL AND RADIATION DOSIMETER COMPRISING SAME AS MATERIAL FOR RADIATION DOSIMETRY | RIKEN (JP) | 2020-10-22 | — | — | US | disclosed |
| EP-3686632-A1 | RADIATION DOSIMETRY SOL OR GEL AND RADIATION DOSIMETER COMPRISING SAME AS MATERIAL FOR RADIATION DOSIMETRY | Riken (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-10138297-B2 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor | AMGEN RESEARCH (MUNICH) GMBH (DE) | 2018-11-27 | — | — | US | disclosed |
| US-20170023681-A1 | PERSONAL AND SELF INDICATING RADIATION ALERT DOSIMETER | NEW YORK UNIVERSITY | 2017-01-26 | — | — | US | disclosed |
| US-20160130338-A1 | Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor | AMGEN RES MUNICH GMBH (DE) | 2016-05-12 | — | — | US | disclosed |
| WO-2003106435-A1 | FUSED-RING PYRIMIDIN-4(3H)-ONE DERIVATIVES, PROCESSES FOR THE PREPARATION AND USES THEREOF | SANKYO COMPANY, LIMITED (JP) | 2003-12-24 | — | — | WO | disclosed |
| EP-0880539-B1 | NUCLEOSIDE ANALOGUES | AMERSHAM BIOSCIENCES UK LTD (GB) | 2003-06-25 | — | — | EP | disclosed |
| US-20030096329-A1 | (1-3)-beta-D-glucan binding domain protein, measuring method using the substance and assay kit | SEIKAGAKU CORPORATION | 2003-05-22 | — | — | US | disclosed |
| EP-1312613-A2 | (1--3)-beta-D-glucan binding domain protein, measuring method using the substance and assay kit | SEIKAGAKU CORPORATION (JP) | 2003-05-21 | — | — | EP | disclosed |
| US-6313286-B1 | NUCLEOSIDE WITH DEGENERATE BASE AND REPORTER MOLECULE; FOR INCORPORATION INTO OLIGONUCLEOTIDES AS LABELS; HYBRIDIZATION; IMMUNOASSAY | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 2001-11-06 | — | — | US | disclosed |
| US-6171807-B1 | MIXING TOGETHER ENDOTOXIN NEUTRALIZING PROTEIN, UREA, AND FLUORESCEIN N-HYDROXYSUCCINIMIDE ESTER IN AN AQUEOUS CITRATE BUFFER SOLUTION, AND ISOLATING THE LABELED PROTEIN; FOR USE IN TESTING | ASSOCIATES OF CAPE COD, INC. | 2001-01-09 | — | — | US | disclosed |
| EP-0880539-A1 | NUCLEOSIDE ANALOGUES | Amersham Pharmacia Biotech UK Limited (GB) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997028177-A1 | NUCLEOSIDE ANALOGUES | AMERSHAM PHARMACIA BIOTECH UK LIMITED (GB) | 1997-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130338-A1 | Antibody Neutralizers of Human Granulocyte Macrophage Colony Stimulating Factor | CSF3R, CSF1R, FCGR3B | FTO 4683/4885MEN1 542/4885MAPT 2915/4885 |
| US-10138297-B2 | Antibody neutralizers of human granulocyte macrophage colony stimulating factor | CSF3R, CSF1R, FCGR3B | FTO 4683/4885MEN1 542/4885MAPT 2915/4885 |
| US-20220305121-A1 | N-ARYL SULFONAMIDE DERIVATIVES AS VACCINE ADJUVANT | TLR1, TLR3, TLR2 | FTO 4113/4885MEN1 4729/4885MAPT 3676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.